adenosine A2A receptor antagonist

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson’s disease

By Stewart A. Factor DO*, Kenneth Wolski MD, Daniel M. Togasaki MD, PhD, Susan Huyck DrPH, Marc Cantillon MD†, T.W. Ho MD‡, Robert A. Hauser MD, MBA and Emmanuelle Pourcher MD